A New White Paper by AHM

Life Sciences is among the more highly regulated industries in business today, with pharmaceutical and related firms subject to scrutiny from federal and state-level regulatory agencies regarding their interactions with healthcare professionals (HCPs). Entering into a Corporate Integrity Agreement (CIA) can be a challenge, but it is by no means an uncommon one. This document is intended both for firms operating under a CIA, as well as those that want to enhance efforts to steer clear of compliance issues and hopefully avoid the need to enter into a CIA.


Download this new AHM White Paper and learn more about:
  • Operational Risk Areas that can Trigger a CIA
  • Key Categories of CIA Compliance
  • Elements of Compliance-Centric Engagements
  • Factors Necessary for Facilitating Compliance-Centric Speaker Programming
  • The Final Frontier of Reporting
  • And more

Avoiding-Risk (2).pngA Not-to-Miss White Paper from AHM

For Life Sciences organizations, information related to compliance is of crucial importance. The industry is enduring close regulatory scrutiny, which is likely to continue to expand in scope. One major challenge involves implementing processes to ensure complete and accurate retention of data and compliance with relevant systems.

Download this white paper and learn about:

  • Important ways to ensure data quality
  • How to address the data challenge
  • How to implement quality results
  • And more

Driven by a multitude of regulatory requirements, disclosure of information relating to relationships in the healthcare field and especially “transfers of value” is now a fact of life for Life Science organizations. With the US e­ffectively taking the lead, other markets have followed or are following a path toward more information transfers, more record keeping, and more complexity, all in the name of the laudable goal of transparency.

Download this white paper and learn more about the cornerstones of meeting global transparency requirements; including the need for a robust technology portfolio linked with service solutions, transparency of data amongst the organization and affiliates, and more.


To someone outside of the Life Science industry, the term meal cap probably sounds innocuous and perhaps a little puzzling. Meal caps are related to verb use – to “cap,” meaning to put a restriction (usually on cost or price) on “something.” In the Life Sciences industry, that most often has to do with payments subject to a range of compliance limitations, especially the wide-ranging Open Payments “Sunshine” Act law in the U.S. or similar laws elsewhere.

The purpose of this paper is to provide perspectives relative to all stakeholders involved with the specific impact of meal caps or hospitality restrictions associated with the Life Sciences manufacturers and health care professionals (HCPs).